Enfortumab vedotin versus platinum rechallenge in post‐platinum, post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study

Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinoma

(2022) Taizo Uchimoto et al.   BJU INTERNATIONAL

Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma

(2022) Lucie Meynard et al.   EUROPEAN JOURNAL OF CANCER

Improved survival in real‐world patients with advanced urothelial carcinoma: A multicenter propensity score‐matched cohort study comparing a period before the introduction of pembrolizumab (2003–2011) and a more recent period (2016–2020)

(2022) Satoru Taguchi et al.   INTERNATIONAL JOURNAL OF UROLOGY

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

(2021) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma

(2021) TETSUYA YUMIOKA et al.   ANTICANCER RESEARCH

The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma

(2021) Richard Cathomas et al.   EUROPEAN UROLOGY

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

(2020) Jonathan Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) Thomas W. Flaig et al.   Journal of the National Comprehensive Cancer Network

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

(2020) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

(2019) Y Fradet et al.   ANNALS OF ONCOLOGY

Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer

(2018) Bernadett Szabados et al.   EUROPEAN UROLOGY

Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer

(2018) Song Ee Park et al.   Journal of Thoracic Oncology

Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen

(2018) Gwenaëlle Gravis et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

(2016) P. M. Challita-Eid et al.   CANCER RESEARCH

Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world

(2015) Satoru Taguchi et al.   WORLD JOURNAL OF UROLOGY

Prognostic Factors for Metastatic Urothelial Carcinoma Undergoing Cisplatin-based Salvage Chemotherapy

(2013) S. Taguchi et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER